CA
NZ
UK
AU
IND
US
Where the monthly high-water-mark market frames the question in terms of Bitcoin's upside potential, Kalshi's companion market on how low Bitcoin will get this year frames the mirror-image downside question. At the time of the latest snapshot, the market implied a 52% probability that …
Kalshi's same-day Bitcoin price market asks a simple yes-or-no question: will BTC be trading above a specific dollar threshold at 5pm EDT today? As of the latest snapshot, the $66,250-or-above contract was priced to imply a 52% probability, while the higher $66,500-or-above contract implied …
Kalshi's Bitcoin price market for Friday at 5pm EDT gives traders a multi-day window to price where BTC is likely to land relative to two key thresholds. At the time of the latest snapshot, the $66,000-or-above contract implied a 58% probability, notably higher than …
Kalshi's monthly market asking how high Bitcoin will get in July frames the question differently from the daily threshold markets: rather than pricing where BTC sits at a single point in time, it prices the probability that Bitcoin touches a given level at any …
Biohaven Ltd. (NYSE: BHVN) shares traded at $14.86, down 3.76% on the day, as the company prepares to present Phase 1 data for its solid tumor candidate BHV-1530 at the ESMO 2026 congress.
Standard BioTools Inc. (NASDAQ: LAB) shares traded at $0.85, down 5.02% on the day, as the company advances two Phase 1 oncology programs, TLN-121 and TLN-372, amid its pending merger with Treeline Biosciences, Inc.
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) shares traded at $25.09, down 1.99% on the day, after the FDA granted Fast Track designation to remlifanserin, also known as ACP-204, under the RADIANT trial program for Alzheimer's disease psychosis.
Immunome Inc. (NASDAQ: IMNM) shares traded at $22.16, down 0.72% on the day, after the company disclosed that Phase 1 dosing has commenced for its immunotherapy candidate 177Lu-IM-3050.
Dogwood Therapeutics Inc. (NASDAQ: DWTX) shares traded at $1.38, unchanged on the day, after the company completed enrollment in its Phase 2b HALT-CINP trial evaluating Halneuron for chemotherapy-induced neuropathic pain.
BioLineRx Ltd. (NASDAQ: BLRX) shares traded at $2.83, down 2.41% on the day, as the company continues to advance GLIX1 in glioblastoma, with Phase 1/2 dosing underway.
Please wait processing your request...